Skip to main content
. Author manuscript; available in PMC: 2014 Sep 12.
Published in final edited form as: Cancer Chemother Pharmacol. 2012 May 24;70(1):65–74. doi: 10.1007/s00280-012-1880-4

Fig. 1.

Fig. 1

Mean (±SD) plasma concentration–time profiles for a sunitinib and SU12662 following administration of sunitinib (50 mg/day on Schedule 2/2) with or without mFOLFOX6, b free platinum following administration of mFOLFOX6 with or without sunitinib, c 5-FU following administration of mFOLFOX6 with or without sunitinib